figshare
Browse
cd-23-0467_table_s5_suppst5.pdf (41.88 kB)

Table S5 from Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer

Download (41.88 kB)
journal contribution
posted on 2024-01-12, 08:21 authored by Sarah P. Suehnholz, Moriah H. Nissan, Hongxin Zhang, Ritika Kundra, Subhiksha Nandakumar, Calvin Lu, Stephanie Carrero, Amanda Dhaneshwar, Nicole Fernandez, Benjamin W. Xu, Maria E. Arcila, Ahmet Zehir, Aijazuddin Syed, A. Rose Brannon, Julia E. Rudolph, Eder Paraiso, Paul J. Sabbatini, Ross L. Levine, Ahmet Dogan, Jianjiong Gao, Marc Ladanyi, Alexander Drilon, Michael F. Berger, David B. Solit, Nikolaus Schultz, Debyani Chakravarty

Table S5: Genes associated with an OncoKB Therapeutic Level of Evidence (1, 2 or 3A) in March of 2017

Funding

OncoKB commercial licensing fees

Prostate Cancer Foundation Award

Marie-Josée and Henry R. Kravis Center for Molecular Oncology

National Institutes of Health (NIH)

History

ARTICLE ABSTRACT

There is a continuing debate about the proportion of cancer patients that benefit from precision oncology, attributable in part to conflicting views as to which molecular alterations are clinically actionable. To quantify the expansion of clinical actionability since 2017, we annotated 47,271 solid tumors sequenced with the MSK-IMPACT clinical assay using two temporally distinct versions of the OncoKB knowledge base deployed 5 years apart. Between 2017 and 2022, we observed an increase from 8.9% to 31.6% in the fraction of tumors harboring a standard care (level 1 or 2) predictive biomarker of therapy response and an almost halving of tumors carrying nonactionable drivers (44.2% to 22.8%). In tumors with limited or no clinical actionability, TP53 (43.2%), KRAS (19.2%), and CDKN2A (12.2%) were the most frequently altered genes. Although clear progress has been made in expanding the availability of precision oncology-based treatment paradigms, our results suggest a continued unmet need for innovative therapeutic strategies, particularly for cancers with currently undruggable oncogenic drivers.See related commentary by Horak and Fröhling, p. 18.This article is featured in Selected Articles from This Issue, p. 5

Usage metrics

    Cancer Discovery

    Categories

    Keywords

    BiomarkersGenetic biomarkers

    Licence

    CC BY

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC